New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances.

Abstract excerpt

The discovery of BRAF and KIT mutations provided the first basis for a molecular classification of cutaneous melanoma on therapeutic grounds. As BRAF-targeted therapy quickly moves toward regulatory approval and incorporation as standard therapy for patients with metastatic disease, proof of concept has also been established for targeting mutated KIT in melanoma. NRAS mutations have long been known to be present...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CDK4 gene
• Share to MITF gene
• Share to Gene Targeting